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Immune responses change during the life of an individual. While this concept has been
well accepted for adaptive immunity, only recently it is becoming clear that the innate
immune responses also acquire distinct features in different phases of life. We believe that
this concept can offer a different interpretation of the pathological manifestations that can
be observed in HBV-infected subjects during the patient’s life. Here, we will review the
age-related immunopathological features of HBV infection and discuss how the different
virological and clinical manifestations might be linked to the developmental pathway of
the immune system from newborns to adults. We will discuss how the age of patients
can affect the degree of inflammatory responses, but not the levels of antiviral specific
immunity. We then propose that the different clinical manifestations occurring during the
natural history of HBV infection are related to the host ability to trigger an inflammatory
immune response.
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Hepatitis B virus is a hepatotropic, non-cytopathic, DNA virus that
chronically infects about 300 million people worldwide. It causes
acute or chronic liver diseases characterized by different levels of
liver inflammation and viral replication. An acute HBV infection
can be resolved without clinical symptoms or with an inflamma-
tory disease of the liver (acute hepatitis). Similarly, persistent HBV
infection can cause minimal pathological manifestations or trigger
a chronic liver inflammation that develops into liver cirrhosis or
cancer (1). These clinical and virological profiles do not only vary
among individuals in relation to their genetic background, dose,
or route of infection but they are also present within the same
individual in relation to his age.
HBV chronic infection is, particularly in Asia, the result of
virus transmission from HBV+ mothers to their infants (1).
HBV infection at birth is characterized by an apparent benign
phase of disease with high HBV replication levels and absence
of markers of liver inflammation [i.e., normal alanine amino-
transferase or aminotransferases (ALT) levels; an enzyme released
by dying hepatocytes] during childhood. This phase, defined as
immune tolerant, is followed by a disease phase in adulthood
characterized by liver inflammatory events and fluctuations in
ALT levels and viral load, known as the immune active/clearance
phase (Figure 1) (1, 2). The favored interpretation of these
different virological and clinical patterns is that during child-
hood there is a phase of immunotolerance, i.e., an absence of
antiviral specific immunity that is lost at the start of adult-
hood when the host immune system actively “combat” HBV
infection (2).
Here, we will review the data that dispute this scenario and
propose an alternative interpretation of these immunopatholog-
ical events based on the new understanding of the age-related
immunological changes.
HBV VERTICAL INFECTION: DOES IT INDUCE IMMUNE
TOLERANCE?
The influence of age on HBV infection starts at birth. Take, for
example, acute hepatitis B infection. In infants or children, HBV
infection rarely causes acute hepatitis (2), while in adults, acute
hepatitis B infection is common and is almost invariably associated
with HBV control due to the induction of an efficient HBV-specific
T- and B-cell response (3). Vertical (mother-to-child) infection in
infants often leads to chronic diseases (in 90% of infection) and it
is thought that the establishment of a persistent infection is due to
immaturity of the neonatal immune system and/or the induction
of “immunotolerance,” i.e., the inability to induce a virus-specific
immune response (2).
This infant’s inability to mount HBV-specific T- and B-cell
responses is supported mainly by data from animal models (i.e.,
HBV transgenic mice) that showed the presence of immunolog-
ical defects, which impair HBV-specific T- and B-cell priming in
neonatal animals (4–6). These data are methodologically robust.
Nevertheless, their significance in relation to HBV pathogenesis
can be questionable, since in HBV transgenic mice, HBV does not
infect the mouse hepatocytes but viruses are produced through the
introduction of HBV–DNA in the mouse genome under the con-
trol of hepatocyte-specific promoters (7, 8). As such, the possibility
that HBV infection might induce priming of adaptive immunity
or activation of innate immunity is excluded “a priori.”
The concept that neonates have a “defective” immune system
is also changing and mounting evidences show that the neona-
tal immune responses defy such simple categorization. Indeed,
recent studies have demonstrated that the immune effectors as
well as regulatory responses are already in place during early fetal
life (9, 10). Furthermore, newborns have been shown to mount a
virus-specific T cell response toward viral infections in early life
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FIGURE 1 | (A) Conventional schematic representation of immune events, HBV replication, and aminotransferases (ALT) levels in children and adults during
chronic HBV infection. (B) Proposed interpretation of the immune events during the non-inflammatory and inflammatory phases of CHB infection.
(11–13). Besides, exposure of the newborn immune system toward
microbes at birth can also modulate the maturation status of the
newborn infant. Epidemiological observations and experimental
data have shown that bacterial colonization and/or immuniza-
tion can protect infants against unrelated pathogen infection by
inducing an increased functional efficiency of their innate immune
system, a process termed “trained immunity” (14). All these ear-
lier reports show that the newborn infant’s immune system is not
“defective” per se; rather, we believe that it is less prone to trigger
a full blown pro-inflammatory reaction, likely as an evolutionary
adaptation to avoid undesirable immune reactions in utero (15).
Therefore, the hypothesis that vertical HBV infection in infants
leads to the induction of immunotolerance remains controversial.
Even though the immunological data both during and after natural
vertical HBV infection are limited, there are several epidemiolog-
ical and experimental evidences that contradict the immunotol-
erance hypothesis during vertical HBV infection. For example,
it has been reported that dendritic cell functionality is normal
or minimally altered in neonates of HBV+ mothers (16, 17)
and the detection of T cells specific for HBV in two indepen-
dent studies performed in HBsAg− children born from HBV+
mothers (18, 19) show that neonates exposed to HBV do not
necessarily develop a defect in T cell priming but can mount a
HBV-specific T cell response. The increase detection of HBV quasi-
species in immunotolerant HBV+ children is compatible with the
presence of an immune pressure (20) and not with tolerance. Sim-
ilarly, the efficacy of HBV vaccination in children born to HBV+
mothers (21, 22) and the better outcome of standard treatment
detected in HBV+ children (23, 24) are at odds with the gen-
eral idea of immunotolerance in HBV-infected children. Similarly,
the “immunotolerance” hypothesis is difficult to reconcile with
epidemiological evidences that HBV-related fulminant hepatitis is
more frequent in children of<1 year of age compared to older sub-
jects (25) or with the observations obtained from malaria–HBV
co-infected young patients in whom reduced parasitemia (26) and
increased incidences of cerebral malaria (27), a Th1-mediated
malaria complication, have been reported. This latter observa-
tion is perhaps more in line with the possibility of an alternative
relationship between HBV and humans during early life.
We have started to investigate the immunological parameters in
the cord blood of newborns of HBV+ mothers. Characterization
of these samples is complex since it is difficult to understand due
to ethical considerations whether neonates are infected by HBV
(i.e., HBV replication in the hepatocytes) or are only exposed
to it (i.e., HBV is present in the circulation but is not able to
establish an infection in hepatocytes). Nevertheless, our prelim-
inary data on cytokine analysis of the sera from neonates born
to HBV+ mothers reveal a cytokine signature compatible with
a Th1-like response (i.e., high levels of IL-12p40 and low levels
of Th2/suppressive cytokines IL-4, IL-5, IL-13, and IL-10) and a
reduced pro-inflammatory cytokine profile (i.e., lower levels of
IL-1b and IL-6) (manuscript in preparation). This Th1 cytokine
signature is more suggestive of a possible symbiotic relationship
between HBV and humans during early life, similar to the one
demonstrated in murine model of persistent herpesvirus infec-
tion (28), than to the induction of a tolerogenic response. More
data need to be gathered to better understand the impact of vertical
HBV infection on humans during the early stages of life.
IMMUNOLOGICAL PARAMETERS IN THE “IMMUNE
TOLERANCE” PHASE OF HBV INFECTION
The existence of an immunotolerance phase of HBV infection
during childhood is supported by clinical and virological mani-
festations. Since HBV is not directly cytopathic and HBV-specific
CD8 T cells control virus spread by killing the infected hepatocytes
(29), it is logical to think that the presence/absence of altered ALT
levels correlates with the presence/absence of HBV-specific T cells
(Figure 1A). Therefore, normality of liver enzymes, detectable in
the majority of HBV-infected children, has been interpreted as an
indication of a lack of HBV-specific T cell response, while ALT
alterations, more likely to occur during adulthood, are interpreted
as an “awakening” of HBV-specific immunity.
Frontiers in Immunology | Immunotherapies and Vaccines September 2014 | Volume 5 | Article 441 | 2
Bertoletti and Hong HBV infection, immunity, and age
In reality, ALT measurement cannot be used as a reliable sur-
rogate of a virus-specific T cell response. Work in adenovirus-
infected mice (30) confirmed that T cell immunity against hepa-
tocytes could take place without serum ALT elevation. Adoptive
transfer of HBV-specific T cells can cause substantial inhibition of
HBV replication without ALT increase through cytokine-mediated
non-cytopathic virus control (31) and HBV-specific T cells quan-
tification in blood and liver is not proportional to ALT levels (32,
33). Robust liver inflammatory events causing ALT elevations are
instead, demonstrated in adult mice and in patients, associated
with a liver infiltrate consisting of granulocytes, monocytes, and
non-antigen-specific T cells (32, 34, 35).
A direct demonstration that the “immunotolerance” phase is
not associated with an absence of virus-specific T cell immu-
nity came directly from our recent study of chronic hepatitis B
(CHB)-infected adolescents. Despite having a clinical and viro-
logical profile labeled as “immunotolerant,” these adolescents
displayed a perfectly normal Th1 T cell response and harbored
HBV-specific T cells that were actually functionally better than the
ones detected in adult CHB patients in the “immune clearance”
phase (36).
AGE-DEPENDENT CHANGES IN IMMUNITY AND
INFLAMMATORY EVENTS DURING VIRAL INFECTIONS
Innate immune responses are not identical during the life of an
individual. TLR-mediated immune function has been shown to
change in different periods of life (37). The production of anti-
inflammatory cytokine (e.g., IL-10) is high in preterm infants,
and it progressively declines over the first years of life but is
superior in children versus adults. In contrast, the production
of pro-inflammatory cytokines (e.g., IL-1b, TNF-alpha) steadily
increases during early life (37) until it reaches the state of chronic
low-grade systemic inflammation called “inflammaging” present
in elderly subjects (38).
Consequently, T cell responses also shift from a Th2/Treg type
response in newborns to a more Th1 response in children/adults
(15) and with a progressive increase in effector memory T cell
pools. These effector memory T cells can respond efficiently to a
cognate infection and are also sensitive to cytokine-mediated acti-
vation (39). The question then arises: can these age-dependent
changes in immune functions explain the different virological
and inflammatory patterns during the natural history of HBV
infection?
Interestingly, the evidence of the impact of age on pathologi-
cal processes can also be observed in other infections. Influenza
virus infection, for example, can cause death due to an increased
inflammatory response in the lung predisposing to bacterial infec-
tion (40) in some but not all individuals. Figure 2 shows the data
on the incidence of both clinical influenza and pneumonia mortal-
ity during the 1918 influenza pandemic in relation to age (40). It is
evident that children, despite experiencing a higher rate of clinical
influenza, had a much lower mortality rate than young adults. This
phenomenon has also been observed in other infections (41). The
immunological mechanisms underlying these different outcomes
have not been experimentally demonstrated but the common
trend is that inflammatory events are less severe in children than in
adults. It is certainly intriguing that the “immunotolerant and the
FIGURE 2 | A comparison of the age-related mortality of influenza (top
panel) and the age-related phases of chronic HBV infection (bottom
panel).
active immune phases” of chronic HBV infection mirrors the dif-
ferent age-related mortality seen in the 1918 influenza pandemic
(Figure 2).
IMMUNOLOGICAL EVENTS DURING HBV INFECTION: AN
ALTERNATIVE HYPOTHESIS
Based on the epidemiological, clinical, and experimental data sum-
marized above, we propose an alternative interpretation of the
immune events occurring during natural HBV infection:
(a) HBV transmission at birth is not exclusively followed by per-
sistent infection and characterized by an inability to mount a
HBV-specific adaptive immunity. Newborns of HBV+ moth-
ers can mount a HBV-specific immune response following
vaccination (22), and the detection of T cells specific for
the HBV core and polymerase antigen (antigens not present
in the HBV prophylactic vaccine) (18, 19) shows that HBV
exposure in utero can prime virus-specific T cells. Further
studies are needed to define the mechanisms/circumstances
underlying this induction. However, the frequent detection of
HBV-specific memory T cells in young, exposed, but unin-
fected subjects (42) imply that the induction of a specific
adaptive immunity after HBV contact at birth or during child-
hood is not a rare event. However, with the exceptions of very
few cases of fulminant hepatitis present at birth (25), HBV-
specific adaptive immunity seems to occur in children without
symptoms of acute hepatitis. Whether this different clinical
phenotype is the result of a quantitative/qualitative defect in
T cell response or a reduced ability of children to mount a
pro-inflammatory response needs to be further evaluated.
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(b) The state of high HBV replication and low ALT levels
present in young CHB patients should be termed the “non-
inflammatory” phase of HBV infection (Figure 1B). Data
obtained from young CHB patients (age between 15 and
30 years old) show that, at least in this period, the absence
of serological markers of liver inflammation is not associ-
ated with an immune profile of general or HBV-specific T cell
tolerance (36). Furthermore, clonal hepatocyte repopulation,
an indirect measurement of targeted killing of HBV-infected
hepatocytes, has been detected in immunotolerant patients
(P. Kennedy and Bill Mason, personal communications). The
hypothesis is that in children, HBV-specific CD8 T cells might
try to contain the HBV infection like in adults but due to
the reduced pro-inflammatory cytokine milieu and the lim-
ited pool of effector/memory T cells, they do not trigger the
non-specific recruitment of inflammatory cells to the liver.
(c) The immune clearance phase of chronic hepatitis, charac-
terized by altered levels of ALT, fluctuations in the HBV
replication levels, and histological signs of liver inflamma-
tion, may be better defined as the “inflammatory” phase of
CHB (Figure 1B). The adult’s propensity to mount pro-
inflammatory immune reactions might explain the clinical,
immunological, and virological profiles of HBV infection in
adults. Liver inflammation can be triggered by HBV-specific
CD8 T cells, but it is unlikely a direct effect since the extent of
liver inflammation is not proportional to the absolute quantity
of HBV-specific CD8 T cells. In adult patients, HBV-specific
T cell response is not proportional to liver inflammation
(32). Similarly, episodes of hepatic flares (heightened liver
inflammation) are observed without any detectable increase of
circulating HBV-specific T cells (43) but are instead associated
with increased level of chemokines (43) and NK cell activation
(44). Changes in liver inflammatory environment might tune
the sensitivity of T cells to antigens (45) and this might indi-
rectly increase HBV-specific T cell activation. Alternatively,
liver inflammatory events might derive directly from pro-
inflammatory reactions trigger by different sources, e.g., bac-
terial products as shown in a model of hepatic steatosis (46).
Changes in the intra-hepatic pro-inflammatory environment
may explain the fluctuations in HBV replication. IL-1beta and
TNF-alpha, the classical pro-inflammatory cytokines, have
inhibitory effects on HBV (47, 48) through the activation
of cytidine deaminases, enzymes that are highly activated in
advanced liver pathologies (49).
There are clinical implications on these alternative inter-
pretations. Firstly, if young CHB patients can mount HBV-
specific immune responses without inducing a full blown pro-
inflammatory reaction, therapies designed to boost HBV-specific
immunity (e.g., vaccine therapy, check points inhibitors) (50)
are more likely to succeed and will be less damaging in these
young patients. Secondly, if we start to evaluate and study CHB
infection in adults in the context of an inflammatory disease
rather than a viral induced disease, anti-inflammatory therapies
designed to inhibit the liver inflammatory events may prove to
be important in controlling HBV infection. The superior effi-
cacy of the anti-platelet therapy in blocking the development of
hepatocellular carcinoma in HBV transgenic mice is one such
example (51, 52).
CONCLUDING REMARKS
Epidemiological and experimental evidences raised doubts that
the natural progression of CHB can be dictated by a simple quan-
titative difference in adaptive immunity. The classic view of HBV
vertical transmission inevitably causing a phase of HBV-specific
immune tolerance, which is lost during adulthood, is not tenable
to our increased understanding of the effect of age on the immune
response and on the HBV-specific immune events.
We are aware that more experimental data need to be gath-
ered to support the alternative scenarios that we have proposed.
Nevertheless, we and others (53) believe that the different clinical
phenotypes of HBV infection in children and adults should no
longer be described based on (1) the mechanisms that have been
exclusively determined in experimental mouse models that do not
establish persistent HBV infection and (2) the clinical observations
on the circulating levels of HBV and ALT.
Having said that, additional data need to be gathered especially
during the early phases of HBV infection, i.e., from HBV-exposed
newborn infants and CHB-infected children, in whom limited
studies have been performed. Moving forward, it is of our inter-
est to test whether HBV+ children harbor HBV-specific immunity
and whether such responses trigger intra-hepatic inflammatory
events only in adults. We are also aware of the potential roles of
many other components of the immune response that needs to be
analyzed; one example is NK cells that are present abundantly in
the liver and might have both antiviral and regulatory effects in
HBV infection (54).
At the moment, there are still many gaps in the knowledge of
HBV infection and we hope that this opinion article might inspire
new avenues of research that can better define the immunopatho-
logical processes of this infectious disease that is affecting a
considerable part of human population.
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